## Nicholas C Cullen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5390381/publications.pdf

Version: 2024-02-01

20 papers 2,523 citations

471061 17 h-index 19 g-index

20 all docs

 $\begin{array}{c} 20 \\ \text{docs citations} \end{array}$ 

20 times ranked 4415 citing authors

#	Article	IF	CITATIONS
1	Harmonization of cortical thickness measurements across scanners and sites. NeuroImage, 2018, 167, 104-120.	2.1	790
2	Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurology, 2019, 76, 791.	4.5	436
3	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. Nature Medicine, 2021, 27, 1034-1042.	15.2	236
4	Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. JAMA Neurology, 2019, 76, 318.	4.5	161
5	Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. Brain, 2020, 143, 3234-3241.	3.7	150
6	Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. Acta Neuropathologica, 2019, 137, 279-296.	3.9	128
7	Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nature Communications, 2021, 12, 3555.	5.8	115
8	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. Acta Neuropathologica, 2018, 136, 363-376.	3.9	114
9	NFL is a marker of treatment response in children with SMA treated with nusinersen. Journal of Neurology, 2019, 266, 2129-2136.	1.8	104
10	The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease. Acta Neuropathologica, 2019, 137, 89-102.	3.9	64
11	Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease. Current Opinion in Neurology, 2021, 34, 266-274.	1.8	54
12	Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition. Scientific Reports, 2021, 11, 1965.	1.6	28
13	Comparing progression biomarkers in clinical trials of early Alzheimer's disease. Annals of Clinical and Translational Neurology, 2020, 7, 1661-1673.	1.7	27
14	Plasma phosphorylated tau181 and neurodegeneration in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2021, 8, 259-265.	1.7	25
15	Cardiac Surgery is Associated with Biomarker Evidence of Neuronal Damage. Journal of Alzheimer's Disease, 2020, 74, 1211-1220.	1.2	22
16	Transient increase in CSF GAP-43 concentration after ischemic stroke. BMC Neurology, 2018, 18, 202.	0.8	21
17	Structural brain measures linked to clinical phenotypes in major depression replicate across clinical centres. Molecular Psychiatry, 2021, 26, 2764-2775.	4.1	21
18	Association of CSF Aβ <sub>38</sub> Levels With Risk of Alzheimer Disease–Related Decline. Neurology, 2022, 98, .	1.5	16

#	Article	IF	CITATIONS
19	Dynamics of extracellular matrix proteins in cerebrospinal fluid and serum and their relation to clinical outcome in human traumatic brain injury. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1565-1573.	1.4	11
20	Associations between cerebrospinal fluid markers of neuroinflammation and longitudinal measurements of white matter lesions. Alzheimer's and Dementia, 2021, 17, .	0.4	0